U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Laryngopharyngeal Dysesthesia

MedGen UID:
230967
•Concept ID:
C1328466
•
Sign or Symptom

Definition

A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLaryngopharyngeal Dysesthesia

Professional guidelines

PubMed

Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda A, Goel R, Berdzik J, Leichman CG, Javle M
Oncology (Williston Park) 2004 Nov;18(13):1671-5; discussion 1676, 1680, 1683-4. PMID: 15648298

Recent clinical studies

Etiology

Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda A, Goel R, Berdzik J, Leichman CG, Javle M
Oncology (Williston Park) 2004 Nov;18(13):1671-5; discussion 1676, 1680, 1683-4. PMID: 15648298
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals
Br J Cancer 2004 Nov 15;91(10):1758-62. doi: 10.1038/sj.bjc.6602217. PMID: 15505621Free PMC Article

Therapy

Dose dependent slurred speech and laryngopharyngeal dysesthesia due to oxaliplatin.
Varghese D, Castelino R, Simha V, Krishnamurthy MN, Gota V
J Oncol Pharm Pract 2022 Oct;28(7):1641-1644. Epub 2022 Feb 4 doi: 10.1177/10781552221077038. PMID: 35119329
Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda A, Goel R, Berdzik J, Leichman CG, Javle M
Oncology (Williston Park) 2004 Nov;18(13):1671-5; discussion 1676, 1680, 1683-4. PMID: 15648298
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals
Br J Cancer 2004 Nov 15;91(10):1758-62. doi: 10.1038/sj.bjc.6602217. PMID: 15505621Free PMC Article
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD
J Clin Oncol 2002 Apr 1;20(7):1759-66. doi: 10.1200/JCO.2002.07.087. PMID: 11919232
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
Díaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortés-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M
Ann Oncol 1998 Jan;9(1):105-8. doi: 10.1023/a:1008200825886. PMID: 9541691

Clinical prediction guides

Dose dependent slurred speech and laryngopharyngeal dysesthesia due to oxaliplatin.
Varghese D, Castelino R, Simha V, Krishnamurthy MN, Gota V
J Oncol Pharm Pract 2022 Oct;28(7):1641-1644. Epub 2022 Feb 4 doi: 10.1177/10781552221077038. PMID: 35119329

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...